Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KRRO 
Frequency Therapeutics Inc (KRRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/14/2025: KRRO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $93.88
1 Year Target Price $93.88
| 6 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.52% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 295.06M USD | Price to earnings Ratio - | 1Y Target Price 93.88 |
Price to earnings Ratio - | 1Y Target Price 93.88 | ||
Volume (30-day avg) 10 | Beta 2.21 | 52 Weeks Range 6.04 - 56.69 | Updated Date 11/13/2025 |
52 Weeks Range 6.04 - 56.69 | Updated Date 11/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.74 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1863.15% |
Management Effectiveness
Return on Assets (TTM) -28.65% | Return on Equity (TTM) -58.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 255070801 | Price to Sales(TTM) 46.98 |
Enterprise Value 255070801 | Price to Sales(TTM) 46.98 | ||
Enterprise Value to Revenue 40.61 | Enterprise Value to EBITDA -5.6 | Shares Outstanding 9390903 | Shares Floating 5744040 |
Shares Outstanding 9390903 | Shares Floating 5744040 | ||
Percent Insiders 6.17 | Percent Institutions 99.52 |
Upturn AI SWOT
Frequency Therapeutics Inc
Company Overview
History and Background
Frequency Therapeutics Inc. (FREQ) was founded in 2014 and is a clinical-stage biotechnology company focused on developing therapeutics to activate progenitor cells within the body to restore function of damaged tissues. Their initial focus is hearing restoration.
Core Business Areas
- Hearing Restoration: Developing therapeutics, particularly progenitor cell activation (PCA) therapies, aimed at regenerating hair cells in the inner ear to restore hearing function. Their main focus is FX-322.
Leadership and Structure
David Lucchino is the CEO. The company has a board of directors and operates with a research and development focus.
Top Products and Market Share
Key Offerings
- FX-322: An investigational drug designed to regenerate hair cells in the inner ear to potentially restore hearing. As a clinical-stage product it has no current revenue or market share. Competition includes companies developing gene therapies and other regenerative approaches for hearing loss.
Market Dynamics
Industry Overview
The biotechnology industry focusing on hearing loss is competitive, with various companies pursuing different approaches, including gene therapy, cell therapy, and pharmaceuticals.
Positioning
Frequency Therapeutics is positioned as a leader in progenitor cell activation for hearing restoration. Its competitive advantage lies in its PCA platform technology.
Total Addressable Market (TAM)
The TAM for hearing loss treatments is significant, estimated in the billions of dollars, given the large global population affected by hearing impairment. Frequency Therapeutics aims to capture a portion of this market with successful products.
Upturn SWOT Analysis
Strengths
- Novel PCA technology platform
- Experienced leadership team
- Strong intellectual property portfolio
Weaknesses
- Clinical stage company with no approved products and associated revenue
- High cash burn rate
- Dependence on successful clinical trial outcomes
Opportunities
- Successful clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion of PCA platform to other therapeutic areas
Threats
- Clinical trial failures
- Competition from other companies developing hearing loss treatments
- Regulatory hurdles
- Funding challenges
Competitors and Market Share
Key Competitors
- AKOU
- SENS
- VRT
Competitive Landscape
Competition is high, with several companies working on novel hearing loss solutions.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress, clinical trial milestones, and collaborations.
Future Projections: Future growth depends on the success of its clinical trials and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Focus is on advancing FX-322 through clinical trials and exploring partnerships.
Summary
Frequency Therapeutics is a high-risk, high-reward clinical-stage biotech company. The key is the success of FX-322's clinical trials. Weakness lies in its financial dependence on clinical trials. It needs to maintain its strong technology and manage its cash flow to survive and thrive in this competitive market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company 10-K filings
- Analyst reports
- Company press releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Frequency Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2023-11-06 | CEO, President, Interim CFO, Principal Financial Officer & Director Dr. Ram Aiyar MBA, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 92 | Website https://www.korrobio.com |
Full time employees 92 | Website https://www.korrobio.com | ||
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.